前十大流通股东累计持有： 1297.46万股，累计占流通股比： 29.32% 一、主要会计数据和财务指标 | 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.4300 | 0.9200 | -53.26 | 1.7600 | | 每股净资产（元） | 14.81 | 14.78 | 0.2 | 18.46 | | 每股公积金(元) | 9.63 | 9.63 | 0 | 12.82 | | 每股未分配利润(元) | 3.91 | 3.90 | 0.26 | 4.37 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 3.88 | 4.1 | -5.37 | 4.65 | | 净利润(亿元) | 0.53 | 1.13 | -53.1 | 1.62 | | 净资产收益率(%) | 2.94 | 6.37 | -53.85 | 10.28 | 数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 10派2. ...

Financial Performance - The net profit attributable to shareholders decreased by 52.83% compared to the previous year, primarily due to the impact of FDA import warnings affecting product sales and the provision for impairment of inventory and receivables [4]. - The company's operating revenue for 2024 was ¥387,893,051.46, a decrease of 5.50% compared to ¥410,470,639.42 in 2023 [18]. - Net profit attributable to shareholders for 2024 was ¥53,093,764.34, down 52.83% from ¥112,564,144.08 in 2023 [18]. - The basic earnings per share for 2024 was ¥0.43, reflecting a decline of 53.26% from ¥0.92 in 2023 [18]. - The company reported a significant drop in net profit after deducting non-recurring gains and losses, which was ¥32,075,608.69 in 2024, down 62.20% from ¥84,858,023.76 in 2023 [18]. - Revenue from the medical device segment was 198.72 million yuan, a decline of 23.56%, accounting for 51.23% of total revenue [61]. - The animal device segment saw revenue increase to 151.39 million yuan, up 20.83%, representing 39.03% of total revenue [61]. - Laboratory consumables revenue surged to 29.54 million yuan, a growth of 66.08%, making up 7.61% of total revenue [61]. Risk Management - There are no significant risks to the company's ongoing operations, and the medical device industry does not face issues such as overcapacity or continuous decline [4]. - The company has outlined potential risk factors and countermeasures in the management discussion and analysis section of the report [4]. - Future development outlooks and forward-looking statements do not constitute substantive commitments to investors, emphasizing the need for rational investment and risk awareness [4]. - The company emphasizes the importance of investor attention to the outlined risk factors and strategies for future development [4]. - The company faces risks related to customer concentration, with the top five clients accounting for a significant portion of revenue, necessitating diversification strategies [118]. - The company is also aware of foreign exchange risks due to its export-oriented sales, primarily denominated in USD, and plans to implement measures to mitigate these risks [120]. Research and Development - The company continues to focus on research and development of new products and technologies, although specific details were not disclosed in the report [4]. - The company has a dedicated R&D team focused on innovation, with established research centers for veterinary puncture instruments and safety syringes [51][52]. - R&D expenses rose by 23.13% year-on-year to CNY 26,394,205.40, reflecting ongoing investment in product development [72]. - R&D investment reached ¥26,394,205.40 in 2024, up from ¥21,436,278.35 in 2023, marking a year-over-year increase of 23.5% [75]. - The company has developed a range of safety products, including "safety insulin syringes" and "safety blood collection needles," aligning with market trends towards safer medical devices [55]. - The company is developing an automated sheath injector to reduce labor costs and improve production efficiency [71]. - The company has completed the development of a precision urine collector, which enhances measurement accuracy for clinical diagnostics [73]. - The company is working on a safety self-destroying indwelling needle to minimize the risk of blood exposure and infection [73]. Market Expansion and Strategy - The company is actively exploring market expansion opportunities and potential mergers and acquisitions to enhance its competitive position [4]. - The company is actively expanding its overseas factory construction and entering emerging markets to mitigate the impact of U.S. tariffs [59]. - The company plans to enhance product R&D efforts to develop high-value products and improve risk resilience [59]. - The company aims to strengthen its market position in high-safety and high-value products while actively expanding its market share [35]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 500 million yuan for potential deals [157]. Corporate Governance - The company has established a comprehensive governance structure, ensuring compliance with relevant laws and regulations, and maintaining effective communication with shareholders through various channels [128]. - The board of directors consists of 9 members, including 3 independent directors, ensuring a balanced governance structure and adherence to regulatory requirements [130]. - The company has a structured governance framework including a shareholders' meeting, board of directors, and supervisory board, ensuring operational independence [139]. - The company has established a remuneration and assessment committee in compliance with relevant laws and regulations [160]. - The company has implemented a "Quality Return Dual Improvement" action plan to enhance product quality and customer satisfaction, although specific details on its disclosure were not provided [126]. Employee and Talent Management - The company has a competitive salary policy, combining base salary and performance-based pay, ensuring compliance with national labor laws [177]. - The company emphasizes talent development through targeted training programs and internal cultural enrichment to enhance employee skills and engagement [178]. - The total number of employees at the end of the reporting period is 783, with 499 in production, 138 in technical roles, and 110 in administration [176]. - The total number of employees with a bachelor's degree or above is 105, indicating a focus on educational qualifications within the workforce [176]. - The company has established a long-term incentive mechanism for core employees through indirect shareholding arrangements [185]. Financial Management - The company reported a total investment of 109,726.24 million RMB for the year 2022, with 20,000 million RMB allocated for liquidity support [104]. - The company has committed to using the raised funds for promised investment projects without any significant violations [101]. - The company has not reported any issues or other circumstances regarding the use and disclosure of raised funds [105]. - The company has a clear exit mechanism for employees who leave under specific circumstances, ensuring the protection of company interests [190]. - The internal control audit report indicates that the company maintained effective financial reporting internal controls as of December 31, 2024, in all material respects [198].

Financial Performance - The company's operating revenue for Q1 2025 was ¥72,709,290.01, a decrease of 34.28% compared to ¥110,633,038.63 in the same period last year[5] - Net profit attributable to shareholders was ¥7,680,170.44, down 69.34% from ¥25,045,442.29 year-on-year[5] - The net profit after deducting non-recurring gains and losses was ¥3,751,442.88, reflecting a decline of 78.81% compared to ¥17,703,983.31 in the previous year[5] - Basic and diluted earnings per share were both ¥0.06, a decrease of 70.00% from ¥0.20 in the same period last year[5] - Operating profit for the current period was ¥8,771,668.48, down 70.4% from ¥29,566,811.75 in the previous period[26] - Net profit for the current period was ¥7,263,799.94, a decline of 70.0% compared to ¥25,045,442.29 in the previous period[26] - Total comprehensive income attributable to the parent company was 7,676,341.95, compared to 25,045,442.29 in the previous period[27] Cash Flow and Assets - The net cash flow from operating activities decreased by 40.24%, amounting to ¥24,974,256.66, down from ¥41,790,114.16 in the previous year[11] - The company's cash and cash equivalents decreased to ¥323,052,115.34 from ¥331,714,012.93, a reduction of 2.0%[21] - Total current assets decreased to ¥1,025,083,767.94 from ¥1,134,334,117.19, a decline of 9.6%[21] - Total non-current assets increased to ¥944,403,424.89 from ¥846,590,930.24, an increase of 11.5%[22] - Total liabilities decreased to ¥147,823,364.57 from ¥166,483,138.90, a reduction of 11.1%[23] - Total equity increased to ¥1,821,663,828.26 from ¥1,814,441,908.53, an increase of 0.1%[23] - Cash inflow from investment activities totaled 608,289,255.61, compared to 317,427,371.11 in the previous period, indicating a significant increase[30] - Cash flow from operating activities decreased by 15% year-over-year[29] - The company’s total cash outflow from operating activities was 83,163,457.06, slightly down from 85,841,219.67 in the previous period[29] Shareholder Information - Total number of common shareholders at the end of the reporting period is 6,731[14] - The largest shareholder, Lu Jun, holds 28.29% of shares, totaling 34,580,000 shares, with 25,935,000 shares pledged[14] - The second-largest shareholder, Lu Weiwei, holds 16.16% of shares, totaling 19,760,000 shares[14] - The top ten shareholders collectively hold significant stakes, with the top three shareholders alone accounting for over 50% of total shares[14] - The company has not disclosed any other significant shareholder relationships or actions that may affect shareholding dynamics[15] - The company is under high executive lock-up restrictions, with all major shareholders' shares subject to lock-up during their tenure[17] Operational Challenges - The company is currently facing an FDA import warning affecting its subsidiary, Jiangsu Caina Medical Technology Co., which may significantly impact future revenue and profits[19] - The company is actively communicating with the FDA to resolve the import warning issue, but the timeline for resolution remains uncertain[19] - The company emphasizes the importance of investor awareness regarding potential risks associated with the FDA warning[19] Other Financial Metrics - Total operating costs decreased to ¥69,274,853.76 from ¥79,627,515.63, reflecting a reduction of 13.0%[25] - Investment income decreased by 59.70% to ¥2,128,789.69, down from ¥5,281,918.63 in the previous year due to reduced interest from redeemed financial products[10] - The company experienced a 97.54% reduction in asset impairment losses, reporting a loss of ¥291,950.27 compared to a loss of ¥11,871,141.16 in the previous year, primarily due to prior year provisions related to FDA issues[10] - The company incurred a foreign currency translation loss of -3,828.49[27]

证券代码：301122 证券简称：采纳股份 公告编号：2025-030 采纳科技股份有限公司 关于 2024 年度计提减值准备的公告 采纳科技股份有限公司（以下简称"公司"）根据《企业会计准则》及《深 圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等 相关规定，对公司及下属子公司各类资产进行了全面核查和减值测试，拟对截至 2024 年 12 月 31 日存在减值迹象的相关资产计提相应减值准备。现将本报告期 （或"本期"，指 2024 年全年，下同）内计提资产减值准备的具体情况公告如 下： 一、本次计提减值准备的情况 经过公司及下属子公司对截至 2024 年 12 月 31 日存在可能发生减值迹象的 资产进行全面清查和减值测试后，计提各项减值准备明细情况如下： | 类别 | 项目 | 本期计提 | 情况说明 | | --- | --- | --- | --- | | | | （万元） | | | 信用减值损失 | 应收款项坏账 | 1,693.80 | 根据公司会计政策对应收款项以预期 信用损失为基础确认的当期损失。并 | | | 损失 | | 根据美国 FDA 事件影响，公司按预计 | ...

证券代码：301122 证券简称：采纳股份 公告编号：2025-028 采纳科技股份有限公司 关于聘请 2025 年度财务及内部控制审计机构的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 采纳科技股份有限公司（以下简称"公司"）于 2025 年 4 月 23 日召开了第 三届董事会第十三次会议、第三届监事会第十二次会议，分别审议通过《关于聘 请 2025 年度财务及内部控制审计机构的议案》，拟聘请中汇会计师事务所（特殊 普通合伙）（以下简称"中汇会计师事务所"）为公司 2025 年度财务及内部控制 审计机构，该事项尚需提交公司 2024 年年度股东大会审议。现将相关情况公告 如下： 一、拟聘任的会计师事务所基本情况 （一）机构信息 1、基本信息 机构名称：中汇会计师事务所（特殊普通合伙） 机构性质：特殊普通合伙企业 统一社会信用代码：91330000087374063A 业务资质：会计师事务所执业证书 是否曾从事过证券服务业务：是 2、人员信息 首席合伙人：高峰 上年度末（2024 年 12 月 31 日）合伙人数量：116 人，上年度末注册会计 师人 ...

2024 年度监事会工作报告 2024 年度，采纳科技股份有限公司（以下简称"公司"）监事会全体成员严 格按照《中华人民共和国公司法》（以下简称"《公司法》"）《中华人民共和国证 券法》（以下简称"《证券法》"）等法律法规及《公司章程》《监事会议事规则》 相关规定认真履行监督职责，依法列席公司董事会和股东大会，维护公司及股东 的合法权益。报告期内，公司监事会对公司规范运作、董事和高级管理人员履职 情况、募集资金使用情况等方面行使监督职责，为公司规范运作、完善和提升治 理水平发挥了积极作用。现将监事会 2024 年度的主要工作报告如下： 一、监事会会议情况 采纳科技股份有限公司 1、公司规范运作情况 本着对全体股东负责的精神，公司监事会根据《公司法》等相关法律法规和 《公司章程》的规定，对公司的决策程序、内部控制制度、公司董事、总经理及 其他高级管理人员执行公司职务的行为，进行了相应地检查监督。监事会认为： 报告期内，公司股东大会、董事会严格依照《公司法》等相关法律法规和《公司 章程》行使职权，履行义务。公司历次股东大会、董事会的召集、召开、表决、 决议等决策程序均符合法律法规的相关规定。公司董事、监事及高级管 ...

董事会关于独立董事独立性评估的专项意见 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 证券代码：301122 证券简称：采纳股份 公告编号：2025-038 采纳科技股份有限公司 采纳科技股份有限公司（以下简称"公司"）董事会根据《上市公司独立董 事管理办法》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公 司规范运作》等要求，就公司现任独立董事刘斌先生、王尚虎先生、夏立扬先生 的独立性情况进行评估并出具如下专项意见： 经核查独立董事刘斌先生、王尚虎先生、夏立扬先生的任职经历及其签署的 相关自查文件。公司董事会认为：上述人员未在公司担任除独立董事以外的任何 职务，也未在公司主要股东公司担任任何职务，与公司以及主要股东之间不存在 利害关系或其他可能妨碍其进行独立客观判断的关系，公司独立董事均符合《上 市公司独立董事管理办法》《深圳证券交易所上市公司自律监管指引第 2 号—— 创业板上市公司规范运作》等法律法规及《公司章程》中关于独立董事的任职资 格及独立性的要求。 采纳科技股份有限公司董事会 2025 年 4 月 23 日 1 / 1 ...

独立董事独立性自查情况 8、本人符合《上市公司独立董事管理办法》第六条规定的独立性要求。 采纳科技股份有限公司董事会： 本人刘斌根据《上市公司独立董事管理办法》等相关法规、规范性文件要求， 就本人符合独立董事独立性任职资格情况进行自查，自查情况如下： 1、本人除担任贵司独立董事外，本人及本人直系亲属、主要社会关系均不 在贵司及其附属企业任职； 2、本人及本人直系亲属不是直接或间接持有贵司已发行股份 1%以上的股 东，也不是贵司前十名股东中自然人股东； 3、本人及本人直系亲属不在直接或间接持有贵司已发行股份 5%以上的股 东单位任职，也不在贵司前五名股东单位任职； 4、本人及本人直系亲属不在贵司控股股东、实际控制人及其附属企业任职； 5、本人不是为贵司及其控股股东、实际控制人或者其各自附属企业提供财 务、法律、咨询等服务的人员； 6、本人未与贵司及其控股股东、实际控制人或者其各自的附属企业有重大 业务往来的单位任职，也不在有重大业务往来单位的控股股东单位任职； 7、本人在最近十二个月内不具有前六项所列任一种情形； 本人保证上述自查内容真实、准确、完整，没有虚假记载、误导性陈述或重 大遗漏；否则，本人愿意承担由此 ...

关于使用剩余超募资金永久补充流动资金的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 采纳科技股份有限公司（以下简称"公司"或"采纳股份"）于 2025 年 4 月 23 日召开了第三届董事会第十三次会议、第三届监事会第十二次会议，审议 通过了《关于使用剩余超募资金永久补充流动资金的议案》，同意公司使用剩余 12,000 万元（实际转出金额含利息收入净额，以转出当日银行结息余额为准）超 募资金永久补充流动资金，上述事项尚需提交公司股东大会审议。现将具体情况 公告如下： 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意采纳科技股份有限公司首次公开发 行股票注册的批复》（证监许可[2021]3937 号），公司获准向社会公开发行人民 币普通股（A 股）股票 2,350.88 万股，每股面值人民币 1 元，发行价格为人民 币 50.31 元/股，募集资金总额为人民币 1,182,727,728.00 元，扣除各项发行费 用人民币 85,465,325.60 元（不含税），实际募集资金净额为人民币 1,097,262,402.40 元，其中超募资金总额 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 采纳科技股份有限公司（以下简称"公司"）于 2025 年 4 月 25 日在巨潮资 讯网（http://www.cninfo.com.cn）上披露《2024 年年度报告全文》及《2024 年 年度报告摘要》。为便于广大投资者更加全面深入地了解公司经营业绩、发展战 略等情况，公司定于 2025 年 4 月 30 日（星期三）15:00-16:00 在"价值在线" （www.ir-online.cn）举办公司 2024 年度业绩说明会，与投资者进行沟通和交 流，广泛听取投资者的意见和建议。 一、说明会召开的时间、地点和方式 会议召开时间：2025 年 4 月 30 日（星期三）15:00-16:00 会议召开地点：价值在线（www.ir-online.cn） 会议召开方式：网络互动方式 证券代码：301122 证券简称：采纳股份 公告编号：2025-039 采纳科技股份有限公司 关于举办 2024 年度业绩说明会的公告 敬请广大投资者积极参与。 特此公告。 采纳科技股份有限公司董事会 2025 年 4 月 23 日 ...